Pfizer CentreOne CPhI Barcelona Pfizer CentreOne CPhI Barcelona

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest news about Forbius aggregated by PharmaCompass.com.

    Client Virtual Booth

    FORBIUS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Forbius
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    701 Brazos Street, Suite 930 Austin, Texas 78701
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://forbius.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/forbius
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Bristol Myers Squibb completes acquisition of Forbius
    Bristol Myers Squibb completes acquisition of Forbius

    http://www.pharmabiz.com/NewsDetails.aspx?aid=131307&sid=2

    PHARMABIZ
    22 Sep 2020
    Share Share
    Bristol Myers Squibb Completes Acquisition of Forbius
    Bristol Myers Squibb Completes Acquisition of Forbius

    https://www.businesswire.com/news/home/20200921005721/en

    BUSINESSWIRE
    21 Sep 2020
    Share Share
    BMS agrees to acquire biotherapeutics developer Forbius
    BMS agrees to acquire biotherapeutics developer Forbius

    https://www.pharmaceutical-technology.com/news/bms-acquires-forbius/

    PHARMACEUTICALTECHNOLOGY
    25 Aug 2020
    Share Share
    Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta
    Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta

    https://www.businesswire.com/news/canadacom/20200824005159/en/Bristol-Myers-Squibb-Enters-Agreement-Acquire-Forbius

    BUSINESSWIRE
    24 Aug 2020
    Share Share
    Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta
    Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta

    https://www.biospace.com/article/releases/bristol-myers-squibb-enters-agreement-to-acquire-forbius-adding-lead-tgf-beta-asset-to-portfolio/?s=79

    BIOSPACE
    24 Aug 2020
    Share Share
    Forbius Completes Phase 1 Oncology Dose-Escalation with AVID200
    Forbius Completes Phase 1 Oncology Dose-Escalation with AVID200

    https://www.businesswire.com/news/home/20191108005112/en/Forbius-Completes-Phase-1-Oncology-Dose-Escalation-AVID200/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    BUSINESSWIRE
    08 Nov 2019
    Share Share
    Forbius Completes Enrollment into Phase 1a Solid Tumor Trial of AVID200
    Forbius Completes Enrollment into Phase 1a Solid Tumor Trial of AVID200

    https://www.businesswire.com/news/home/20191014005195/en

    BUSINESSWIRE
    14 Oct 2019
    Share Share
    Forbius: Phase 2 Clinical Data with Tumor-Selective Anti-EGFR ADC AVID100
    Forbius: Phase 2 Clinical Data with Tumor-Selective Anti-EGFR ADC AVID100

    https://www.businesswire.com/news/home/20191010005243/en/Forbius-Phase-2-Clinical-Data-Tumor-Selective-Anti-EGFR/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==

    BUSINESS WIRE
    11 Oct 2019
    Share Share
    Forbius: First Patient Dosed in a Phase 1b Myelofibrosis Trial of AVID200
    Forbius: First Patient Dosed in a Phase 1b Myelofibrosis Trial of AVID200

    https://www.businesswire.com/news/home/20190424006165/en

    BUSINESSWIRE
    24 Apr 2019
    Share Share
    Forbius Announces First Patient Dosed in Ph2a EGFR-Overexpressing (TNBC)
    Forbius Announces First Patient Dosed in Ph2a EGFR-Overexpressing (TNBC)

    https://www.businesswire.com/news/home/20190422005566/en/Forbius-Announces-Patient-Dosed-Phase-2a-EGFR-Overexpressing/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    BUSINESSWIRE
    23 Apr 2019
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    seqens-2023-10-02

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search